Prognostic Significance of Immune Cell Populations Identified by Machine Learning in Colorectal Cancer Using Routine Hematoxylin and Eosin-Stained Sections.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
PMID:

Abstract

PURPOSE: Although high T-cell density is a well-established favorable prognostic factor in colorectal cancer, the prognostic significance of tumor-associated plasma cells, neutrophils, and eosinophils is less well-defined.

Authors

  • Juha P Väyrynen
    Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Mai Chan Lau
    Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Koichiro Haruki
    Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery The Jikei University School of Medicine Tokyo Japan.
  • Sara A Väyrynen
    Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Andressa Dias Costa
    Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Jennifer Borowsky
    Conjoint Gastroenterology Department, QIMR Berghofer Medical Research Institute, Queensland, Australia.
  • Melissa Zhao
    University of California San Diego School of Medicine, La Jolla, CA, USA.
  • Kenji Fujiyoshi
    Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Kota Arima
    Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Tyler S Twombly
    Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Junko Kishikawa
    Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Simeng Gu
    Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Saina Aminmozaffari
    Department of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Shanshan Shi
    CICU, Children's Hospital, Zhejiang University School of Medicine, 310052 Hangzhou, Zhejiang, China.
  • Yoshifumi Baba
    Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Naohiko Akimoto
    Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Tomotaka Ugai
    Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Annacarolina Da Silva
    Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Mingyang Song
    Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
  • Kana Wu
    Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
  • Andrew T Chan
    Harvard Medical School, Boston, MA; Division of Gastroenterology, Massachusetts General Hospital, Boston, MA.
  • Reiko Nishihara
    Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Charles S Fuchs
    See the Notes section for the full list of authors' affiliations.
  • Jeffrey A Meyerhardt
    See the Notes section for the full list of authors' affiliations.
  • Marios Giannakis
    Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Shuji Ogino
    Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Jonathan A Nowak
    Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. janowak@bwh.harvard.edu.